Core Viewpoint - The insider trading case involving Jiang Wei, the actual controller of Haohai Biological Technology (688366.SH), has concluded with a total penalty of 19.34 million yuan, highlighting governance concerns within the company as it faces growth challenges and declining performance [1][2][5]. Group 1: Insider Trading Case - Jiang Wei was penalized by the China Securities Regulatory Commission (CSRC) for insider trading and advising others to trade securities, resulting in a total fine and confiscation of 19.34 million yuan [1][5]. - The investigation lasted seven months, reflecting the current regulatory environment's strict stance against insider trading, with half of the CSRC's administrative penalties this year related to such cases [5][7]. - Jiang Wei has never held a position in the listed company and does not participate in daily operations, yet he and his wife control 45.82% of the company's shares [1][5]. Group 2: Company Performance and Governance - Haohai Biological Technology is experiencing a growth bottleneck, with 2024 revenue at 2.698 billion yuan, a mere 1.64% increase, marking the first single-digit growth since 2021 [2][10]. - The company has seen a decline in both revenue and net profit in the first three quarters of 2025, with revenue down 8.47% and net profit down over 10% [2]. - The governance structure is questioned as Jiang Wei's influence persists despite his absence from operational roles, raising concerns about the "behind-the-scenes boss" model [8][12]. Group 3: Business Challenges - The company faces significant challenges in its ophthalmology segment, with revenue from artificial lenses down 14.06% and viscoelastic agents down 19.53% due to centralized procurement policies [10]. - Although the aesthetic medicine segment remains a growth driver, the growth rate of hyaluronic acid products has sharply decreased from 95.45% in 2023 to 23.23% [10]. - Haohai is attempting to diversify by acquiring a 19.8% stake in Ruijie Biological for 38.35 million yuan, despite the target company being in a loss-making state [10].

Core Viewpoint - Shanghai Haohai Biological Technology Co., Ltd. (Haohai) has announced the acquisition of the remaining 20% stake in Shenzhen New Industry Ophthalmology Technology Co., Ltd. for 74 million yuan, aiming to enhance its market competitiveness in ophthalmic products amid declining performance in its core business [1][3]. Group 1: Acquisition Details - Haohai's wholly-owned subsidiary, Shanghai Haohai Pharmaceutical Technology, will acquire the remaining 20% stake in New Industry Ophthalmology, completing a nine-year strategic layout that began with a 60% stake acquisition in November 2016 [1][2]. - New Industry Ophthalmology specializes in manufacturing and selling orthokeratology lenses and intraocular lenses, as well as distributing various imported ophthalmic products in mainland China [1]. Group 2: Financial Performance - As of December 31, 2024, New Industry Ophthalmology's total assets were valued at 250 million yuan, with projected after-tax profits of 32.735 million yuan for 2023, 22.0062 million yuan for 2024, and 16.1877 million yuan for the first half of 2025 [2]. - The acquisition is expected to improve management and operational efficiency, thereby enhancing the competitiveness of Haohai's ophthalmic products [2]. Group 3: Business Challenges - Haohai's overall performance has been under pressure, with a significant slowdown in revenue growth. In 2024, the company reported revenue of 2.698 billion yuan, reflecting a mere 1.64% year-on-year increase, a stark contrast to the double-digit growth seen from 2021 to 2023 [3]. - The company's three main business segments, including ophthalmology, experienced revenue declines in the first half of 2025, with ophthalmic products down by 18.61% [4]. Group 4: Strategic Response - The acquisition of New Industry Ophthalmology is viewed as a strategic move to address declining performance, with Haohai planning to enhance its product offerings and market presence in the ophthalmic sector [6]. - The company aims to promote its self-developed orthokeratology lenses and expand its product line to improve market share, despite ongoing challenges from price reductions due to national and provincial procurement policies [5][6].